BACIL PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.82 INR | +3.88% |
|
+32.35% | +336.05% |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 20.14 | 13.55 | 9.718 | 18.38 | 33.75 | 32.28 |
| Enterprise Value (EV) 1 | 9.13 | 9.502 | 9.191 | 17.75 | 29.16 | 30.29 |
| P/E ratio | -0.54 x | -3.97 x | -3.06 x | -7.61 x | -0.87 x | -32.2 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -3.08 x | -3.53 x | -5.09 x | -11 x | -18.8 x | -17.1 x |
| EV / FCF | 0.46 x | -7.04 x | -7.76 x | -13.6 x | -1.14 x | -25.9 x |
| FCF Yield | 217% | -14.2% | -12.9% | -7.34% | -87.4% | -3.86% |
| Price to Book | 0.9 x | 0.71 x | 0.7 x | 1.32 x | 2.76 x | 2.94 x |
| Nbr of stocks (in thousands) | 5,890 | 5,890 | 5,890 | 5,890 | 5,890 | 5,890 |
| Reference price 2 | 3.420 | 2.300 | 1.650 | 3.120 | 5.730 | 5.480 |
| Announcement Date | 14/08/18 | 06/09/19 | 08/09/20 | 03/09/21 | 07/09/22 | 24/08/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -2.969 | -2.693 | -1.804 | -1.617 | -1.55 | -1.77 |
| EBIT 1 | -3.071 | -2.784 | -1.886 | -1.666 | -1.587 | -1.797 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -37.51 | -3.435 | -3.156 | -2.397 | -38.6 | -1.019 |
| Net income 1 | -37.5 | -3.424 | -3.152 | -2.392 | -38.6 | -1.019 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -6.370 | -0.5800 | -0.5400 | -0.4100 | -6.550 | -0.1700 |
| Free Cash Flow 1 | 19.81 | -1.349 | -1.184 | -1.304 | -25.49 | -1.168 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 14/08/18 | 06/09/19 | 08/09/20 | 03/09/21 | 07/09/22 | 24/08/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 11 | 4.04 | 0.53 | 0.62 | 4.59 | 1.99 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 19.8 | -1.35 | -1.18 | -1.3 | -25.5 | -1.17 |
| ROE (net income / shareholders' equity) | -86.5% | -16.5% | -19.1% | -17.2% | -295% | -8.77% |
| ROA (Net income/ Total Assets) | -3.33% | -3.74% | -2.72% | -2.54% | -3.7% | -9.36% |
| Assets 1 | 1,125 | 91.55 | 115.7 | 94.11 | 1,043 | 10.88 |
| Book Value Per Share 2 | 3.800 | 3.240 | 2.350 | 2.360 | 2.080 | 1.870 |
| Cash Flow per Share 2 | 0.4700 | 0.1500 | 0.0700 | 0.1700 | 0.3900 | 0.0500 |
| Capex 1 | 3.02 | 0.04 | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 14/08/18 | 06/09/19 | 08/09/20 | 03/09/21 | 07/09/22 | 24/08/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- BACPHAR6 Stock
- Financials Bacil Pharma Limited